Medicare Part D Redesign Could Expand Rebate-Driven Formulary Exclusions In Program
Executive Summary
Increased application of utilization management controls expected as plans face higher costs under the redesign. However, the formulary advantages available to drugs in the protected classes may lead developers to sharpen their focus on those categories.
You may also be interested in...
‘Sleeper Issue:’ How Part B Drugs May Be Impacted By Medicare Part D Redesign
If changes to stand-alone Part D plans mandated by the IRA drive a switch to MA plans, the changing enrollment could drive more uptake of physician-administered drugs – but also more utilization management.
Part D In 2024: Premium Increases, Shrinking Choices Signal Early Impact Of IRA Redesign
More impactful benefit changes coming in 2025; will destabilization among standalone plans follow?
Rebates In Part D: HHS Argues Scrutiny Of Impact On Formularies, Beneficiaries Not Needed Now
New GAO recommendations springing from recent Medicare Part D cost and access trends related to rebates may not be relevant going forward because the IRA price negotiation program and benefit redesign will significantly change the landscape, HHS says.